A massive observational study led by Dr. Josephine Tolan of the McGovern Medical School at UTHealth Houston suggests that GLP-1 receptor agonists can lower the risk of heart issues and infections after elective surgery.. The research indicates that these medications, commonly used for weight loss and diabetes, may provide critical protection during the peri-operative period.
The 2 million patient sample from the EPIC COSMOS database
The scale of this analysis is significant, drawing from the EPIC COSMOS database which aggregates data from 40,000 clinics and over 1,700 hospitals. Between January 2016 and December 2024, researchers tracked more than two million adults undergoing elective procedures that lasted at least one hour and required a minimum 24-hour hospital stay.
According to the report, 145,610 of these patients were using GLP-1 receptor agonists, such as tirzepatide and semaglutide, before their operations. By applying statistical matching, the research team was able to compare these users against a similar cohort of non-users to isolate the effects of the medication on surgical outcomes.
An 11 percent drop in major cardiovascular events
The findings reveal a notable reduction in Major Adverse Cardiovascular Events (MACE), a category that includes strokes, heart attacks, myocardial injury, and death. As the study reported, MACE occurred in 1 percent of GLP-1 users compared to 1.1 percent of non-users, representing an 11 percent lower odds ratio for the drug cohort.
Postoperative infections also saw a decline among those taking the medications. Surgical site infections, pneumonia, sepsis, and urinary tract infections were observed in 4.9 percent of GLP-1 users versus 5.3 percent of non-users, which translates to an 8 percent reduction in odds. These figures suggest that the protective effects of the drugs persist even during the high-inflammation window immediately surrounding a surgical procedure.
Beyond blood sugar: Modulating inflammatory pathways
While semaglutide and tirzepatide are primarily known for metabolic control and glucose regulation, Dr. Josephine Tolan suggests these medications may modulate inflammatory pathways. This is particularly relevant because the period surrounding surgery typically triggers a pronounced inflammatory response in the body, which can complicate recovery.
This shift in understanding suggests that GLP-1 drugs could be viewed as more than just diabetes or obesity treatments.. By potentially dampening systemic inflammation, these agents may act as a biological shield, reducing the likelihood of the severe cardiovascular and infectious compllications that often plague high-risk surgical patients.
The aspiration risk and the gastric emptying debate
Despite these benefits, a critical tension remains regarding the risk of pulmonary aspiration during anesthesia. Because GLP-1 drugs slow gastric emptying, some anesthesiologists worry that patients may retain gastric juices even after standard pre-operative fasting, which could lead to dangerous complications during intubation.
Dr. Jessica Duncan of Ivím Health has noted that while the real-world scope of the UTHealth Houston study is impressive, randomized trials are still required to determine the exact balance between these cardiovascular benefits and the risk of aspiration.. Until such trials are completed, the medical community remains divided on whether to withhold these agents before surgery or follow current U.S. guidance that favors an individualized approach.
Comments 0